OTCM
OCLG
Market cap0kUSD
Aug 21, Last price
0.00USD
1Q
-99.00%
Jan 2017
-99.89%
Name
Oncologix Tech Inc
Chart & performance
P/E
—
P/S
0.00
EPS
—
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
291.58%
Revenues
3m
-28.96%
Net income
-2m
L+28.23%
CFO
-24k
L
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Oncologix Tech, Inc. is a biopharmaceutical company whose main products include DNAGO and genomego which provides clinical genetic testing on all 20,000+ genes encompassing over 7,000 rare genetic diseases. It also previously operated in personal home care services and the manufacturing and distribution of medical technologies. The company was formerly known as BestNet Communications Corp. and changed its name to Oncologix Tech, Inc. in January 2007.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2022‑08 | 2021‑08 | 2020‑08 | 2019‑08 | 2017‑08 | 2016‑08 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||